Chyong-huey H. Lai

Chyong-huey H. Lai

Linkou Branch
Taoyuan, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 163 publications

A Successful Multimodal Treatment for High-Grade Serous Ovarian Cancer with BRCA2 Heterozygous Deletion with Multiple Recurrences: A Case Report.

A Successful Multimodal Treatment for High-Grade Serous Ovarian Cancer with BRCA2 Heterozygous Deletion with Multiple Recurrences: A Case Report.

Journal: Case reports in oncology

Published: March 19, 2026

E-cadherin-driven interleukin-6 expression promotes autophagy-mediated platinum resistance in ovarian clear cell carcinoma.

E-cadherin-driven interleukin-6 expression promotes autophagy-mediated platinum resistance in ovarian clear cell carcinoma.

Journal: Cancer gene therapy

Published: December 14, 2025

Promising response to neoadjuvant pembrolizumab and low-dose chemotherapy in advanced endometrial cancer: A preliminary report.

Promising response to neoadjuvant pembrolizumab and low-dose chemotherapy in advanced endometrial cancer: A preliminary report.

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: November 25, 2025

Diagnostic accuracy of MDCT for preoperative peritoneal cancer index estimation in advanced ovarian cancer undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC): a Sugarbaker-based analysis.

Diagnostic accuracy of MDCT for preoperative peritoneal cancer index estimation in advanced ovarian cancer undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC): a Sugarbaker-based analysis.

Journal: European radiology

Published: October 29, 2025

Dual PI3K/AKT/mTOR and CDK4/6 inhibition suppresses survivin to overcome uterine dedifferentiated endometrial carcinoma.

Dual PI3K/AKT/mTOR and CDK4/6 inhibition suppresses survivin to overcome uterine dedifferentiated endometrial carcinoma.

Journal: Cancer gene therapy

Published: August 31, 2025

Cervical cancer in Taiwan.

Cervical cancer in Taiwan.

Journal: Taiwanese journal of obstetrics & gynecology

Published: April 28, 2025

Distinct genomic subgroups and mutational patterns in undifferentiated/dedifferentiated endometrial carcinoma.

Distinct genomic subgroups and mutational patterns in undifferentiated/dedifferentiated endometrial carcinoma.

Journal: BMC cancer

Published: March 15, 2025

Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression through disrupted ribosome biogenesis.

Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression through disrupted ribosome biogenesis.

Journal: Journal of molecular medicine (Berlin, Germany)

Published: March 03, 2025

Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.

Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.

Journal: Journal of gynecologic oncology

Published: February 05, 2025

Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers.

Metastatic Cervical Cancer in the Asia-Pacific Region: Current Treatment Landscape and Barriers.

Journal: Cancer research communications

Published: December 29, 2024

Complete remission of endometrial cancer stage IVC treated with multimodality treatment including immunotherapy and maintenance PARP inhibitor - A case report.

Complete remission of endometrial cancer stage IVC treated with multimodality treatment including immunotherapy and maintenance PARP inhibitor - A case report.

Journal: Taiwanese journal of obstetrics & gynecology

Published: December 06, 2024

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 16, 2024

Showing 1-12 of 163

Last Updated: 09/26/2026